Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowIttai Kidron rated Brightpoint “Sector Perform” from “Sector Outperformer,” prompting investors to devalue the shares by $1.50, to $11.38.
The CIBC downgrade is an aberration since Brightpoint announced in December that it would buy rival CellStar Corp. for $88 million. Lazard Capital Markets maintained its “Buy” rating, Jeffries & Co. reiterated its “Buy” recommendation and Cowen & Co. has stayed with its “Neutral” rating.
Assets of the Coppell, Texas, company are expected to gain Brightpoint entry into CellStar’s U.S. and Latin American markets.
Please enable JavaScript to view this content.